Datasets:
Inabia-AI
/
continued-pretraining-jsonl

Dataset card Data Studio Files
xet
 Community
1
text
stringlengths
1
5.46k
3.2 Responsibilities .................................................................................................................... 27
3.3 Meetings and Minutes .......................................................................................................... 27
3.4 Procedural Rules .................................................................................................................. 28
3.5 Decision-Making .................................................................................................................. 28
3.6 Limits on Decision-Making ................................................................................................. 29
3.7 Alliance Managers ............................................................................................................... 29
3.8 Discontinuation of Committees ............................................................................................ 29
3.9 Interactions Between a Committee and Internal Teams ....................................................... 30
3.10 Subcommittees ..................................................................................................................... 30
3.11 Expenses ............................................................................................................................... 30
3.12 Authority .............................................................................................................................. 30
ARTICLE 4 GRANT OF LICENSES ........................................................................................................ 30
4.1 Licenses to AbbVie .............................................................................................................. 30
4.2 Sublicensing Rights .............................................................................................................. 31
4.3 UPenn Rights ....................................................................................................................... 31
4.4 No Other Rights ................................................................................................................... 32
4.5 Confirmatory Patent License ................................................................................................ 32
4.6 In-License Agreements ........................................................................................................ 32
4.7 Rights in Bankruptcy............................................................................................................ 32
ARTICLE 5 POST-LICENSE OPTION EXERCISE ACTIVITIES .......................................................... 33
5.1 Anima Transition Obligation Upon License Option Exercise ............................................. 33
5.2 AbbVie Development and Commercialization .................................................................... 33
5.3 AbbVie Diligence Obligation .............................................................................................. 33
ARTICLE 6 GENERAL PROVISIONS RELATING TO ACTIVITIES .................................................. 34
6.1 Compliance .......................................................................................................................... 34
6.2 Regulatory Activities ........................................................................................................... 34
6.3 Performance by Affiliates and Sublicensees ........................................................................ 34
6.4 Subcontracting ..................................................................................................................... 34
6.5 Records and Audits .............................................................................................................. 35
ARTICLE 7 UPFRONT FEE; MILESTONES AND ROYALTIES; PAYMENTS .................................. 35
7.1 Upfront Fee .......................................................................................................................... 35
7.2 Additional Target Program Fee ............................................................................................ 35
7.3 Collaboration Target Substitution Fee ................................................................................. 35
7.4 License Option Period Extension Fee .................................................................................. 37
7.5 License Option Exercise Fee ................................................................................................ 38
7.6 Development and Regulatory Milestone Payments ............................................................. 38
7.7 Sales-Based Milestone Payments ......................................................................................... 40
7.8 Royalties ............................................................................................................................... 41
7.9 Royalty Term ....................................................................................................................... 42
7.10 Royalty and Milestone Adjustments .................................................................................... 42
7.11 Estimated Sales Levels ......................................................................................................... 43
7.12 Reports; Payment of Royalty ............................................................................................... 44
7.13 Financial Records ................................................................................................................. 44
7.14 Audit; Audit Dispute. ........................................................................................................... 44
7.15 Methods of Payments; Offsets ............................................................................................. 44
7.16 Taxes .................................................................................................................................... 45
7.17 Late Payments ...................................................................................................................... 46
7.18 Financial Obligations under In-License Agreements ........................................................... 46
ARTICLE 8 EXCLUSIVITY; CHANGE OF CONTROL ......................................................................... 46
8.1 Exclusivity ........................................................................................................................... 46
8.2 Change of Control of Anima ................................................................................................ 51
ARTICLE 9 INTELLECTUAL PROPERTY RIGHTS ............................................................................. 52
9.1 Ownership of Intellectual Property; Disclosure ................................................................... 52
9.2 AbbVie Patents .................................................................................................................... 52
9.3 Patent Prosecution and Maintenance ................................................................................... 53
9.4 Enforcement of Licensed IP ................................................................................................. 54
9.5 Infringement Claims by Third Parties .................................................................................. 54
9.6 Invalidity or Unenforceability Defenses or Actions ............................................................ 55
9.7 Third Party Licenses ............................................................................................................ 55
9.8 Product Trademarks ............................................................................................................. 56
9.9 Inventor's Remuneration ...................................................................................................... 56
9.10 International Nonproprietary Name ..................................................................................... 56
ARTICLE 10 CONFIDENTIALITY .......................................................................................................... 56
10.1 Product Information ............................................................................................................. 56
10.2 Confidentiality Obligations .................................................................................................. 57
10.3 Permitted Disclosures........................................................................................................... 58
10.4 Use of Name ......................................................................................................................... 59
10.5 Public Announcements......................................................................................................... 59
10.6 Publications .......................................................................................................................... 60
10.7 Return of Confidential Information ..................................................................................... 60
10.8 Survival ................................................................................................................................ 60
ARTICLE 11 REPRESENTATIONS AND WARRANTIES .................................................................... 60
11.1 Representations and Warranties of Both Parties .................................................................. 60
11.2 Representations, Warranties, and Covenants, as applicable, of Anima ............................... 61
11.3 Compliance with Applicable Law ........................................................................................ 66
11.4 Additional Covenants of Anima ........................................................................................... 66
11.5 Anti-Bribery and Anti-Corruption Compliance ................................................................... 66
11.6 Disclaimer ............................................................................................................................ 66
ARTICLE 12 INDEMNIFICATION; INSURANCE ................................................................................. 66
12.1 Indemnification by AbbVie .................................................................................................. 66
12.2 Indemnification by Anima ................................................................................................... 67
12.3 Procedure ............................................................................................................................. 68
12.4 Insurance .............................................................................................................................. 69
12.5 Limitation of Liability .......................................................................................................... 70
ARTICLE 13 TERM AND TERMINATION ............................................................................................ 70
13.1 Term ..................................................................................................................................... 70
13.2 Termination .......................................................................................................................... 71
13.3 Modification in Lieu of Termination ................................................................................... 72
13.4 Effects of Termination ......................................................................................................... 73
13.5 Effects of Termination in Terminated Territory .................................................................. 74
13.6 Accrued Rights; Surviving Provisions of the Agreement .................................................... 74
ARTICLE 14 MISCELLANEOUS ............................................................................................................ 75
14.1 Governing Law; Service ...................................................................................................... 75
14.2 Dispute Resolution ............................................................................................................... 75
14.3 Assignment ........................................................................................................................... 76
14.4 Force Majeure ...................................................................................................................... 77
14.5 Notices ................................................................................................................................. 77
14.6 Export Clause ....................................................................................................................... 78
14.7 Waiver; Non-Exclusion of Remedies ................................................................................... 78
14.8 Further Assurance ................................................................................................................ 78